204 related articles for article (PubMed ID: 30254187)
1. Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain.
Azhar A; Kim YJ; Haider A; Hui D; Balankari VR; Epner MC; Park M; Liu DD; Williams J; Frisbee-Hume SE; Allo JA; Bruera E
Oncologist; 2019 Jan; 24(1):125-131. PubMed ID: 30254187
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Observational Study on the Characteristics of Pain and Associated Factors of Breakthrough Pain in Advanced
Fan R; Li X; Yang S; Bu X; Chen Y; Wang Y; Qiu C
Pain Res Manag; 2022; 2022():8943292. PubMed ID: 35463627
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS).
Mercadante S; Marchetti P; Cuomo A; Caraceni A; Mediati RD; Mammucari M; Natoli S; Lazzari M; Dauri M; Airoldi M; Azzarello G; Bandera M; Blasi L; Cartenì G; Chiurazzi B; Costanzo BVP; Degiovanni D; Fusco F; Guardamagna V; Iaffaioli V; Liguori S; Lorusso V; Mameli S; Mattioli R; Mazzei T; Melotti RM; Menardo V; Miotti D; Moroso S; De Santis S; Orsetti R; Papa A; Ricci S; Sabato AF; Scelzi E; Sofia M; Tonini G; Aielli F; Valle A;
Adv Ther; 2017 Jan; 34(1):120-135. PubMed ID: 27873235
[TBL] [Abstract][Full Text] [Related]
4. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
5. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
Yen TY; Chiou JF; Chiang WY; Su WH; Huang MY; Hu MH; Wu SC; Lai YL
Medicine (Baltimore); 2018 Jul; 97(30):e11593. PubMed ID: 30045291
[TBL] [Abstract][Full Text] [Related]
6. Standard therapy with opioids in chronic pain management : ORTIBER study.
Gatti A; Reale C; Occhioni R; Luzi M; Canneti A; De Polo C; Gubernari M; Mammucari M; Fabrizio Sabato A
Clin Drug Investig; 2009; 29 Suppl 1():17-23. PubMed ID: 19445551
[TBL] [Abstract][Full Text] [Related]
7. Fentanyl buccal tablet.
Messina J; Darwish M; Fine PG
Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
[TBL] [Abstract][Full Text] [Related]
8. [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
Yomiya K; Kaneshima M; Kyosaka B; Warita E; Hosonuma R; Osato S
Gan To Kagaku Ryoho; 2017 Apr; 44(4):289-293. PubMed ID: 28428506
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
10. Predicting the risk for aberrant opioid use behavior in patients receiving outpatient supportive care consultation at a comprehensive cancer center.
Yennurajalingam S; Edwards T; Arthur JA; Lu Z; Najera J; Nguyen K; Manju J; Kuriakose L; Wu J; Liu D; Williams JL; Reddy SK; Bruera E
Cancer; 2018 Oct; 124(19):3942-3949. PubMed ID: 30192372
[TBL] [Abstract][Full Text] [Related]
11. A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.
Chiou TJ; Chao TC; Chao TY; Huang JS; Chang YF; Wang CH
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1179. PubMed ID: 32721110
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
[TBL] [Abstract][Full Text] [Related]
13. The opioid rotation ratio of hydrocodone to strong opioids in cancer patients.
Reddy A; Yennurajalingam S; Desai H; Reddy S; de la Cruz M; Wu J; Liu D; Rodriguez EM; Waletich J; Shin SH; Gayle V; Patel P; Dalal S; Vidal M; Tanco K; Arthur J; Tallie K; Williams J; Silvestre J; Bruera E
Oncologist; 2014 Nov; 19(11):1186-93. PubMed ID: 25342316
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T
Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907
[TBL] [Abstract][Full Text] [Related]
17. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
Portenoy RK; Messina J; Xie F; Peppin J
Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
[TBL] [Abstract][Full Text] [Related]
18. Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
